A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome

Learn more about:
Related Clinical Trial
A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome Improving Care of Prader-Willi Syndrome : Evaluation of a New Care Program Combining Adapted Physical Activity, Nutrition and Therapeutic Education Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Willi Syndrome Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS Assessment of CAI in Adults With PWS. Probiotic Treatment for Prader-Willi Syndrome Prader-Willi Syndrome Body Composition Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation Global Growth Hormone Study in Adults With Prader-Willi Syndrome Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies Home-based SSP on Individuals With PWS A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) PREPL in Health and Disease Correlation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome Proof of Concept Study of Vagus Nerve Stimulation Characterization of Transcriptional Regulators of Ghrelin Hormone Which Causes Genetic Obesity Post Exercise Irisin Levels in PWS Patients Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Macronutrient Regulation of Ghrelin and Peptide YY PWS European Blood Bank for Infants and Controls From 0 to 48 Months PWS Outcomes Assessment Study Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo Exploring Stress and Coping Behaviors of the Major Carer Whose Children With Prader-Willi Syndrome An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome Effects of Progressive Elastic Band Resistance Training An Open-Label Study of DCCR Tablet in Patients With PWS Ghrelin Suppression by Octreotide in Prader-Willi Mitochondrial Complex I Dysfunction in PWS Natural History Study of Serious Medical Events in PWS Liraglutide Use in Prader-Willi Syndrome Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome Growth Hormone Use in Adults With Prader-Willi Syndrome The Intestinal Function in People With Prader-Willi Syndrome Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory Fiber Intervention on Gut Microbiota in Children With Prader-Willi Syndrome Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome tVNS in Children With Prader-Willi Syndrome Effects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome Prader-Willi Syndrome Macronutrient Study Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome Prader-Willi Syndrome and Appetite Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS) Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome A Study of GLWL-01 in Patients With Prader-Willi Syndrome Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome Register of Patients With Prader-Willi Syndrome Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome Intranasal Oxytocin for Infants With Prader-Willi Syndrome Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome Stress and Brain Response Using MEG in PWS Therapeutic Effects of Hippotherapy in Children With Prader-Willi Syndrome Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome Hypoglycemia in Prader-Willi Syndrome Oxytocin Trial in Prader-Willi Syndrome Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years

Brief Title

A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome

Official Title

A Phase 3, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome

Brief Summary

      This is a Phase 3 open-label extension (OLE) study in patients diagnosed with Prader-Willi
      Syndrome (PWS) who completed the Maintenance Period of the randomized, placebo-controlled
      Phase 2/3 study SCOUT-015.

      The primary objective of this study is to assess the long-term safety and tolerability of
      RAD011.
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Assess the safety of RAD011 by evaluating the incidence and severity of adverse events reported


Condition

Prader-Willi Syndrome

Intervention

RAD011

Study Arms / Comparison Groups

 RAD011
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

200

Start Date

January 2023

Completion Date

August 2025

Primary Completion Date

August 2025

Eligibility Criteria

        Inclusion Criteria:

          -  Presence of a parent/legal guardian that is able to consent for their participation.
             Parent/caregiver/legal guardian can complete the required assessments throughout the
             study. Patient Consent/Assent will be obtained if the patient is 8 years of age or
             older and has the mental capacity to understand and sign a written consent/assent form
             and/or give verbal assent;

          -  Patient completed treatment on the SCOUT-015 study through Visit 14 (Week 34);

          -  If female, is either not of childbearing potential (defined as premenarchal or
             surgically sterile [bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy]) or practicing one of the following medically acceptable methods of
             birth control up to 4 weeks after the last dose of

        RAD011 or placebo:

        Exclusion Criteria:

          -  Significant acute condition (active infection, uncontrolled diabetes, any other
             uncontrolled chronic condition) including but not limited to clinically significant
             laboratory abnormality, or medical or psychosocial condition that may preclude the
             patient from participating in the study, at the Investigator's discretion;

          -  Positive urine test for drugs of abuse, including tetrahydrocannabinol (THC), or known
             history of drug, alcohol, or substance abuse;

          -  Significant risk of committing suicide based on history, psychiatric examination, or
             based on the Investigator's judgment;

          -  Significant non-compliance issues (IP misuse or abuse, study visit participation,
             etc.) during the patient's SCOUT-015 participation based on the Investigator's
             judgement.

          -  Pregnant (determined by a positive urine pregnancy test) or lactating female;

          -  Concurrent participation in any other interventional study involving an
             investigational product, gene therapy, or device.
      

Gender

All

Ages

8 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

, 617-444-1800, [email protected]



Administrative Informations


NCT ID

NCT05387798

Organization ID

SCOUT-016


Responsible Party

Sponsor

Study Sponsor

Radius Pharmaceuticals, Inc.


Study Sponsor

, , 


Verification Date

May 2022